Objective: This study aimed to evaluate the prognostic value of the Controlling Nutritional Status (CONUT) score for predicting 1-year major adverse cardiovascular events (MACE) in patients hospitalized for acute coronary syndrome (ACS) and treated with the potent P2Y₁₂ inhibitor ticagrelor.Materials and Methods: A total of 817 consecutive ACS patients admitted between September 2024 and July 2025 were prospectively enrolled. Patients with advanced malignancy, active infection, end-stage liver disease, or receiving other P2Y₁₂ inhibitors were excluded. The CONUT score was calculated from serum albumin, total cholesterol, and lymphocyte count. The primary endpoint was 1-year MACE, defined as a composite of cardiovascular death, myocardial infarction, stroke, or unplanned revascularization.Results: MACE occurred in 72 patients (8.8%). Patients with MACE had higher age, hypertension, diabetes, and chronic kidney disease rates, and lower LVEF and albumin levels (p
Building similarity graph...
Analyzing shared references across papers
Loading...
Abdullah Kadir Dolu
Ahmet Anıl Başkurt
Yusuf Demir
Meandros Medical And Dental Journal
Izmir University
Building similarity graph...
Analyzing shared references across papers
Loading...
Dolu et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69c4cc98fdc3bde448917eff — DOI: https://doi.org/10.69601/meandrosmdj.1793562